Alcanza Clinical Research Expands Network With Acquisition of CNS Healthcare

What Happened

Alcanza Clinical Research has acquired CNS Healthcare, a long-standing independent network specializing in neuroscience and behavioral health trials. The move integrates CNS Healthcare’s five Florida and Tennessee locations into Alcanza’s broader national footprint.

Founded in 1996, CNS Healthcare brings three decades of experience in clinical study execution. The acquisition includes the firm’s mobile research unit and its established team of investigators, aimed at increasing Alcanza's therapeutic reach.

Leadership from both organizations stated that the merger aligns with shared goals regarding participant diversity and site performance. The deal is part of Alcanza’s ongoing effort to consolidate high-performing research sites under a unified, patient-focused network.

The Core Points

Alcanza Clinical Research acquires CNS Healthcare to expand its national site network.
The deal adds five research locations in Florida and Tennessee plus a mobile trial vehicle.
CNS Healthcare brings 30 years of experience in neuroscience and behavioral health research.
The acquisition supports Alcanza’s goal of broadening clinical trial access for under-represented groups.
Combined resources aim to enhance trial execution, participant engagement, and overall site performance.

Context in 60 Seconds

The clinical research industry is currently moving toward consolidation as large, integrated networks seek to streamline trial operations and improve data quality. By scaling their infrastructure, these organizations aim to better navigate the complexities of multi-site study management and patient recruitment.

This trend is increasingly driven by a focus on accessibility and site-based diversity, ensuring that clinical testing reaches a broader demographic of patients. As competition for high-quality, reliable site performance intensifies, companies are prioritizing the acquisition of established research entities with proven track records in specific therapeutic fields.

Bottom Line

The acquisition bolsters Alcanza’s national research capacity and deepens its expertise in neuroscience, supporting its goal to standardize clinical trial access across diverse communities.

Loading briefing details...